Conference MDAngle: AUA 2024 Metastatic Prostate Cancer

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

The American Urological Association 2024 Annual Meeting, held in San Antonio, Texas, on May 3-6, showcased advancements in metastatic prostate cancer, including updates from trials such as VISION and PROpel. Key sessions explored molecular imaging, immunotherapy, and genetic testing, emphasizing prostate-specific membrane antigen (PSMA) targeting and multidisciplinary approaches. Sessions in the realm of advancements in metastatic prostate cancer included updated guidance on molecular imaging from new joint AUA/ASTRO/SUO guidelines on salvage therapy for prostate cancer. Results from PSMAfore and a study on actinium-J591 showed promise, and the TARGET trial underscored the need for genetic testing, especially in younger patients.

Kelvin Moses, MD, PhD

Associate Professor, Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee

“There are several areas in the realm of metastatic prostate cancer that have shown some promise in certain modalities. One of the areas that has some very interesting reports is in the area of theranostics, or essentially therapeutic treatment in using diagnostic imaging…Another big area that was reported on is in metastasis-directed therapy There were five trials that have shown that radiation given to oligometastatic disease has shown significant improvement in radiographic progression-free survival.”

Mohammed M. Mahmoud, MD, MS

Assistant Professor, Department of Surgery, Southern Illinois University; Assistant Professor of Surgery and Biostatistics, Department of Surgery, Division of Urology, Memorial Springfield Hospital and HSHS St. John Hospital, Springfield, Illinois

“Metastatic prostate cancer takeaways from AUA 2024 included a lot of emphasis on PSMA targeting for diagnostics and therapeutics, genetic testing, directed therapy, multimodal and multidisciplinary treatments.”

Preconference Considerations

AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer

In anticipation of AUA 2024, Dr Moses shares his excitement about the upcoming conference and highlights some areas he is eager to explore. These include the latest information on PSMA PET imaging, new data on PARP inhibitors, and updates from trials evaluating combination therapies.

Quick Clinical Takeaways

AUA 2024: Advancements in PSMA-Targeted Therapy and Genetic Testing

Dr Mahmoud found AUA 2024's sessions on metastatic prostate cancer enlightening, featuring discussions on PSMA targeting, genetic testing, and multidisciplinary treatments. Highlights included data from PSMAfore showing efficacy of lutetium-based therapy promising results from PSMA-targeted actinium-J591, and the TARGET study's emphasis on the importance of genetic testing in choosing treatment. He eagerly anticipates further research on these novel strategies.

How Will My Patients Benefit?

AUA 2024: Insights on Emerging Therapies in Metastatic Prostate Cancer

Dr Moses discusses exciting advancements in metastatic prostate cancer treatment presented at the 2024 AUA Annual Meeting. Lutetium-based PSMA therapy and metastasis-directed therapy show promise in improving outcomes for patients with advanced disease, highlighting the evolving landscape of therapeutic options in prostate cancer management. These findings underscore the need for continued research and the potential for personalized treatment approaches to optimize patient care.

Polling Question

Summary

The American Urological Association 2024 Annual Meeting in San Antonio, Texas, featured cutting-edge research on metastatic prostate cancer. Trials like VISION and PROpel presented updates, while sessions focused on molecular imaging, immunotherapy, and genetic testing, highlighting PSMA targeting and multidisciplinary care. Dr Moses discussed promising findings from theranostics, particularly lutetium-based PSMA therapy, and the RESIST-PC trial showed significant benefits in PSA reduction and response rates. Dr Mahmoud emphasized the importance of genetic testing, especially in de novo metastases, and highlighted the TARGET trial's use of online tools for diagnosis. The PSMAfore trial and studies on actinium-J591 demonstrated potential, indicating a shift toward personalized and effective therapies for advanced prostate cancer.

Resources

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.